Biomarkers Market Size, Share, and Trends 2024 to 2034

Biomarkers Market Size and Companies

The global biomarkers market size was USD 82.30 billion in 2023, accounted for USD 94.24 billion in 2024, and is expected to reach around USD 318.76 billion by 2033. The market is expanding at a solid CAGR of 14.5% over the forecast period 2024 to 2033.

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Biomarkers Market Key Takeaways

• North America has held a revenue share of more than 45.18% in 2023.
• By type, the safety segment has accounted revenue share of 37.9% of the total revenue in 2023.
• By application, the drug discovery & development segment will dominate the market with a revenue share of 32.95% in 2023.
• By disease, the cancer segment captured a revenue share of 36.8% in 2023.

U.S. Biomarkers Market Size and Growth 2024 to 2033

The U.S. biomarkers market size was estimated at USD 26.08 billion in 2023 and is predicted to be worth around USD 107.12 billion by 2033, at a CAGR of 15.2% from 2024 to 2033.

North America is Estimated to be the Largest Market for Biomarkers

The research report covers key trends and prospects of biomarkers products across different geographical regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Geographically, biomarkers market is conquered by North America owing to high incidence of cancer and existence of state-of-the-art healthcare infrastructure. On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate, on account of increasing research and development investment by major market players and initiatives taken by governments to boost the biopharmaceutical sector.

Key market Insights:

Biomarkers have presented a major boost for early detection of cancer which can be a crucial development in the field of cancer diagnostics. Early detection can be a major advantage in the treatment and management of cancer. Biomarkers are vital as molecular markers of the physiological state of a cell at a definite time. Active genes, their corresponding protein products, and supplementary organic compounds produced by the cell generate these markers. As a regular cell progresses through the intricate process of transformation into a cancerous state, biomarkers can prove vital for the screening of early cancer and individuals at risk of evolving cancer. Consistent, non-invasive examinations for the early recognition of cancer improve the likelihoods for successful treatment and preclude the usage of an invasive biopsy.

Crucial factors accountable for market growth are:

• Rising incidences of cancer
• Increasing focus on establishment of biomarker-based diagnostic methods
• Growing number of contract research organizations
• High incidence of chronic ailments
• Increasing research on use of biomarkers in early detection of cancer
• Rapidly expanding applications of biomarkers in diagnostics
  

Biomarkers Market Scope

Type Insights

Safety Biomarkers Segment Reported Foremost Market Stake in 2023

Safety Biomarkers segment recorded the prime market share in the global biomarkers market by type in 2023. Increasing use in the process of drug discovery is the major reason for high market share of safety biomarkers. Other factors such as increasing investment in research and development to develop new diagnostic procedures is expected to increase the usage of the safety biomarkers over the estimate period.

The efficacy biomarkers are projected grow at the highest CAGR during the forecast period mainly due to new product launches in the near future.

Disease Insights

Cancer is Projected to Dominate the Disease Segment of Biomarkers Market Revenue

Cancer is one of the most widely studied disorder in the world. Constant research in the cancer field has revealed that, use of biomarkers in early detection of the deadly disease can be a turning point in cancer management. Strong product pipeline of major manufacturers related to cancer biomarkers is expected to further boost the popularity of biomarkers in cancer management.

Neurological Diseases segment will expand at a significant CAGR during the forecast time-frame.

Application Insights

Drug Discovery & Development Projected to Dominate the Application Segment of Biomarkers Market Revenue

The use of biomarkers is on a constant rise in drug discovery and development majorly due to the advantages offered by biomarkers to scaleup the clinical development stage. These factors contribute to the growth of drug discovery & development segment.

Biomarkers Market Companies

• Bio-Rad Laboratories, Inc.
• Qiagen
• Epigenomics AG
• Abbott
• Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Johnson & Johnson Services, Inc.
• Abbott
• Siemens
• Thermo Fisher Scientific, Inc.

Major Market Segments Covered:

By Type

• Validation
• Efficacy
• Safety

By Disease

• Neurological Diseases
• Cancer
• Immunological Diseases
• Cardiovascular Diseases
• Others

By Application

• Personalized Medicines
• Drug Discovery & Development
• Diagnostics
• Others

By Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• United Kingdom
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa